← Back to Search

Cytokine

Recombinant Interleukin-7 for Myelodysplastic Syndrome

Phase 1 & 2

Waitlist Available

Led By Gheath Al-Atrash

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial is testing the side effects and best dose of a drug called recombinant interleukin-7 in patients who have had a particular type of stem cell transplant. This transplant uses stem cells from a donor that is only partially matched to the patient, and the drug may help the transplant "take" better and help the patient's immune system recover.

Eligible Conditions

Cord Blood Transplant Recipient
Myelodysplastic Syndrome
Myeloproliferative Neoplasms
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Dose Limiting Toxicities

Secondary outcome measures

Overall Survival

Side effects data

From 2023 Phase 1 & 2 trial • 1 Patients • NCT03941769

100%

Fall

100%

Urinary Tract Infection

100%

ANC Decreased

100%

White blood cell decreased

100%

Increased ALT

100%

80%

60%

40%

20%

Study treatment Arm

Supportive Care (Recombinant Interleukin-7)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Supportive care (recombinant interleukin-7)Experimental Treatment1 Intervention

Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Recombinant Interleukin-7

2020

Completed Phase 2

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,152 Total Patients Enrolled

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,780 Total Patients Enrolled

Gheath Al-AtrashPrincipal InvestigatorM.D. Anderson Cancer Center

2 Previous Clinical Trials

54 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this investigation accept new participants?

"Affirmative, the clinical trial is actively enrolling patients; information on clinicialtrials.gov confirms as much. It was initially posted on September 29th 2020 and last updated on September 6th 2022. The research requires 21 participants to be found at a single site of study."

Answered by AI

To what extent is the patient population participating in this clinical trial?

"Correct. Clinicaltrials.gov hosts data that reveals this medical research has been recruiting since its inception on September 29th 2020 and is still actively searching for 21 volunteers from a single centre."

Answered by AI

Are there any previous research initiatives concerning Recombinant Interleukin-7?

"Presently, only 3 Recombinant Interleukin-7 clinical trials are ongoing, none of which have reached Phase 3. Although the research is mainly conducted in Saint Louis, Missouri, 12 other sites are running studies for this treatment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

2020. "2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03941769.